Evidence map›Paper›PMID 36809659›Full record

ArticleJournal of nephrology2023

Usefulness of urinary calprotectin as a novel marker differentiating functional from structural acute kidney injury in the critical care setting.

Jomol Sara John, R V Deepthi, Grace Rebekah, Savit B Prabhu, P Ajitkumar, Georgie Mathew, Indira Agarwal

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of nephrology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Jomol Sara JohnChristian Medical College and Hospital, Christian Medical College Vellore, Vellore, Tamil Nadu, India.
R V DeepthiChristian Medical College and Hospital, Christian Medical College Vellore, Vellore, Tamil Nadu, India.
Grace RebekahChristian Medical College and Hospital, Christian Medical College Vellore, Vellore, Tamil Nadu, India.
Savit B PrabhuChristian Medical College and Hospital, Christian Medical College Vellore, Vellore, Tamil Nadu, India.
P AjitkumarChristian Medical College and Hospital, Christian Medical College Vellore, Vellore, Tamil Nadu, India.
Georgie MathewChristian Medical College and Hospital, Christian Medical College Vellore, Vellore, Tamil Nadu, India.
Indira AgarwalChristian Medical College and Hospital, Christian Medical College Vellore, Vellore, Tamil Nadu, India. indiraagarwal@cmcvellore.ac.in.ORCID http://orcid.org/0000-0003-4746-2782
Christian Medical College, Vellore · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBiomarkers are fundamental tools for differentiating between types of acute kidney injury (AKI) and may thus be crucial in management and prognosis. We report on a recently described biomarker, calprotectin, that appears to be a promising candidate in differentiating hypovolemic/functional AKI from intrinsic/structural AKI, whose acknowledgement may play a role in improving outcomes. We aimed to study the efficacy of urinary calprotectin in differentiating these two forms of AKI. The effect of fluid administration on the subsequent clinical course of AKI, its severity and the outcomes were also studied. METHODOLOGY: Children who presented with conditions predisposing to AKI or with diagnosis of AKI were included. Urine samples for calprotectin analysis were collected and stored at - 20 ºC for analysis at the end of the study. Fluids were administered as per clinical conditions, followed by intravenous furosemide 1 mg/kg, and patients were observed closely for at least 72 h. Children with serum creatinine normalization and clinical improvement were classified as with functional AKI, while those with no response were classified as with structural AKI. Urine calprotectin levels between these two groups were compared. Statistical analysis was performed with SPSS 21.0 software.

resultsOf the 56 children enrolled, 26 were classified as with functional AKI and 30 as with structural AKI. Stage 3 AKI was observed in 48.2% of patients and stage 2 AKI in 33.8%. Mean urine output, creatinine and stage of AKI improved with fluid and furosemide or furosemide alone (OR 6.08, 95% CI 1.65-27.23) (p < 0.01). A positive response to fluid challenge was in favor of functional AKI (OR 6.08, 95% CI 1.65-27.23) (p = 0.008). Presence of edema, sepsis and need for dialysis were hallmarks of structural AKI (p < 0.05). Urine calprotectin/creatinine values were 6 times higher in structural AKI compared to functional AKI. Urine calprotectin/creatinine ratio showed the best sensitivity (63.3%) and specificity (80.7%) at a cut-off value of 1 mcg/mL in differentiating the two types of AKI.

conclusionUrinary calprotectin is a promising biomarker that may help differentiating structural from functional AKI in children.

Indexed as

Acute Kidney InjuryFurosemideBiomarkersChildCreatinineCritical CareHumansLeukocyte L1 Antigen ComplexBiomarkersCreatinineFurosemideLeukocyte L1 Antigen ComplexAcute kidney injuryFunctional AKIIntrinsic AKIUrinary calprotectin

Identifiers

PMID36809659
OpenAlexW4321436829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.